N-Acetyl-Ser-Asp-Lys-Pro acetate (Synonyms: Ac-SDKP acetate) |
Catalog No.GC63718
One-Click Copy Product Info
|
N-Acetyl-Ser-Asp-Lys-Pro acetate is an endogenous tetrapeptide secreted by bone marrow, which is a specific substrate for the N-terminal site of angiotensin-converting enzyme (ACE).
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
N-Acetyl-Ser-Asp-Lys-Pro acetate is an endogenous tetrapeptide secreted by bone marrow, which is a specific substrate for the N-terminal site of angiotensin-converting enzyme (ACE) [1]. N-Acetyl-Ser-Asp-Lys-Pro acetate inhibits hematopoietic stem cells from entering the S phase, participates in the regulation of hematopoietic stem cell proliferation, and can block a stem cell-specific proliferation stimulating factor, selectively acting on quiescent progenitors [2]. N-Acetyl-Ser-Asp-Lys-Pro acetate has been widely used to inhibit the differentiation of hematopoietic stem cells and tissue fibrosis[3].
In vitro, N-Acetyl-Ser-Asp-Lys-Pro acetate treatment (1nM) for 24 hours significantly inhibited the inhibitory effect of S17092 (100μg/ml) on the proliferation of U87-MG cells, and induced Akt phosphorylation[4]. Treatment with 1nM N-Acetyl-Ser-Asp-Lys-Pro acetate for 24 hours significantly inhibited the cell cycle progression of rat cardiac fibroblasts from the G0/G1 phase to the S phase, and led to a decrease in the phosphorylation and nuclear translocation of Smad2[5]. Treatment with 100nM N-Acetyl-Ser-Asp-Lys-Pro acetate for 72 hours significantly inhibited the increase in MMP-2 and MMP-9 protein levels induced by IL-1β in rat cardiac fibroblasts, and reduced collagenase activity[6].
In vivo, N-Acetyl-Ser-Asp-Lys-Pro acetate treatment via daily subcutaneous injection at a dose of 800μg/kg for 3 weeks alleviated proteinuria and renal fibrosis in the hypertensive rat model induced by 5/6 nephrectomy, and improved renal function[7]. Daily subcutaneous injection of 800μg/kg dose of N-Acetyl-Ser-Asp-Lys-Pro acetate was administered for 12 weeks to prevent inflammatory cell infiltration, collagen deposition, downregulation of renin expression and proteinuria in hypertensive mice [8].
References:
[1] Stéphan J P, Melaine N, Ézan E, et al. Source, catabolism and role of the tetrapeptide N-Acetyl-Ser-Asp-Lys-Pro acetate within the testis[J]. Journal of Cell Science, 2000, 113(1): 113-121.
[2] Rousseau A, Michaud A, Chauvet M T, et al. The hemoregulatory peptide N-Acetyl-Ser-Asp-Lys-Pro acetate is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme (∗)[J]. Journal of Biological Chemistry, 1995, 270(8): 3656-3661.
[3] Douglas R G, Ehlers M R, Sturrock E D. Antifibrotic peptide N-Acetyl-Ser-Asp-Lys-Pro acetate (Ac-SDKP): opportunities for angiotensin-converting enzyme inhibitor design[J]. Clinical & Experimental Pharmacology & Physiology, 2013, 40(8).
[4] Hu P, Li B, Zhang W, et al. AcSDKP regulates cell proliferation through the PI3KCA/Akt signaling pathway[J]. PloS one, 2013, 8(11): e79321.
[5] Pokharel S, Rasoul S, Roks A J M, et al. N-Acetyl-Ser-Asp-Lys-Pro acetate inhibits phosphorylation of Smad2 in cardiac fibroblasts[J]. Hypertension, 2002, 40(2): 155-161.
[6] Rhaleb N E, Pokharel S, Sharma U C, et al. N-Acetyl-Ser-Asp-Lys-Pro acetate inhibits interleukin-1β-mediated matrix metalloproteinase activation in cardiac fibroblasts[J]. Pflügers Archiv-European Journal of Physiology, 2013, 465(10): 1487-1495.
[7] Liao T D, Yang X P, D'Ambrosio M, et al. N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure research[J]. Hypertension, 2010, 55(2): 459-467.
[8] Rhaleb N E, Pokharel S, Sharma U, et al. Renal protective effects of N-Acetyl-Ser-Asp-Lys-Pro acetate in deoxycorticosterone acetate–salt hypertensive mice[J]. Journal of hypertension, 2011, 29(2): 330-338.
| Cell experiment [1]: | |
Cell lines | Rat cardiac fibroblasts |
Preparation Method | Rat cardiac fibroblasts were cultured at 37°C and 5% CO2 in DMEM medium supplemented with 10% fetal bovine serum (FBS), 1% L-glutamate, 50U/ml penicillin, and 0.1g/l streptomycin. Cells were plated at a density of 1.2×104 cells/ml in a 96-well plate with growth medium for 24h, and then were incubated with the different concentrations of N-Acetyl-Ser-Asp-Lys-Pro acetate (0, 0.01, 0.1, and 1nM) for 24h, analyzed the cell viability. |
Reaction Conditions | 0, 0.01, 0.1, and 1nM; 24h |
Applications | N-Acetyl-Ser-Asp-Lys-Pro acetate treatment significantly inhibited cell viability of Rat cardiac fibroblasts in a concentration-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male Sprague Dawley rats |
Preparation Method | Male Sprague Dawley rats weighing 275 to 300g were housed in an air-conditioned room with a 12h light/dark cycle and received standard laboratory rat chow and tap water. Rats were allowed 7 days to adjust to their new environment. Before all of the surgical procedures, rats were given analgesia (2mg/kg of butorphanol; s.c.) and anesthesia (50mg/kg of sodium pentobarbital; i.p.). Rats were anesthetized and 5/6Nx was performed by unilateral nephrectomy plus ligation of lower and upper renal arterial branches of the contralateral kidney with a 6-0 silk suture. Ligation was deemed successful when two thirds of the kidney turned dark red. The sham-operated group underwent a similar surgical procedure except that the suture around the renal artery was not tightened. An osmotic minipump filled with N-Acetyl-Ser-Asp-Lys-Pro acetate (800μg/kg/day) for 3 weeks or vehicle (0.01M acetic acid saline solution) was implanted s.c. between the shoulder blades. At the end of the research, the kidneys were collected for analysis. |
Dosage form | 800μg/kg/day for 3 weeks; s.c. |
Applications | N-Acetyl-Ser-Asp-Lys-Pro acetate treatment attenuated renal fibrosis and improved the renal function in rats. |
References: | |
| Cas No. | SDF | ||
| Synonyms | Ac-SDKP acetate | ||
| Formula | C22H37N5O11 | M.Wt | 547.56 |
| Solubility | DMSO : 100 mg/mL (182.63 mM; Need ultrasonic) | Storage | -20°C, stored under nitrogen |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.8263 mL | 9.1314 mL | 18.2628 mL |
| 5 mM | 365.3 μL | 1.8263 mL | 3.6526 mL |
| 10 mM | 182.6 μL | 913.1 μL | 1.8263 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 17 reference(s) in Google Scholar.)